By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


SEARCH JOBS

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.

Formerly called Antivirals, Inc.

YEAR FOUNDED:

1980

LEADERSHIP:

CEO: Ed Kaye, M.D.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: avi@avibio.com
Ownership: Public

Web Site: Sarepta
Employees: 48
Symbol: SRPT
 



Industry
Biotechnology






Company News
Sarepta (SRPT) Announces Fourth Quarter And Full-Year 2016 Financial Results And Recent Corporate Developments 3/1/2017 7:03:05 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 3/1/2017 6:46:42 AM
Sarepta (SRPT) Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead (GILD) for $125 Million 2/21/2017 5:52:30 AM
Sarepta (SRPT) To Announce Fourth Quarter And Full-Year 2016 Financial Results And Recent Corporate Developments On February 28, 2017 2/15/2017 8:07:11 AM
Sarepta (SRPT) Under Pressure As Marathon Pharma Emflaza's Wins FDA Approval for DMD 2/10/2017 6:05:07 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2/1/2017 7:30:28 AM
JPM17: Sarepta (SRPT)'s New Numbers Impress Investors, Stock Gained $300 Million Overnight 1/11/2017 5:48:10 AM
Sarepta (SRPT) Release: Biotech Enters Into License Agreement With Nationwide Children’s Hospital For Galgt2 Gene Therapy Program 1/10/2017 7:22:44 AM
Sarepta (SRPT) Release: Biotech Enters Into Research Agreement And Option Agreement With Nationwide Children’s Hospital For Microdystrophin Gene Therapy Program 1/10/2017 7:21:47 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 1/3/2017 9:45:06 AM
12345678910...
//-->